Physician profile
John M Morgan
NPI 1407890353
$3,601.99
in general payments reported to CMS, 2019-2025
30 companies · $818 in 2025
The $818 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $539 · 2021: $463 · 2022: $242 · 2023: $520 · 2024: $771 · 2025: $818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,233.64 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Medtronic Vascular, INC. | $469.56 | 2019-2020 | |
| Abbott Laboratories | $276.54 | 2020-2025 | Mitraclip, Assurity |
| Amgen INC. | $199.10 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $164.59 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $151.85 | 2025 | |
| Abiomed | $147.26 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.94 | 2024-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $102.83 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.04 | 2019-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $82.88 | 2024-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $77.66 | 2021-2025 | Watchman Flx |
| Pfizer INC. | $66.76 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $54.86 | 2019-2023 | |
| Impulse Dynamics (USA) INC. | $48.15 | 2025 | Optimizer |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $40.61 | 2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $32.59 | 2024-2025 | Amvuttra |
| Edwards Lifesciences Corporation | $30.00 | 2025 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $28.86 | 2025 | Uptravi, Opsumit |
| Novo Nordisk INC | $24.67 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $23.19 | 2025 | |
| Philips North America LLC | $21.71 | 2024 | (Cm9) Amb Mon & Diag Und |
| Lexicon Pharmaceuticals, INC. | $18.56 | 2024 | |
| Braemar Manufacturing, LLC | $18.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.32 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $16.95 | 2024 | Arcalyst |
| Csl Behring | $15.27 | 2020 | |
| Lilly USA, LLC | $15.12 | 2025 | Mounjaro, Zepbound |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Currax Pharmaceuticals LLC | $14.29 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.